Published in final edited form as:

Tetrahedron. 2011 July 29; 67(30): 5487–5493. doi:10.1016/j.tet.2011.05.046.

Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection

Jong Hyun Cho^a, Franck Amblard^a, Steven J. Coats^b, and Raymond F. Schinazi^{a,*}

^aCenter for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, GA 30033, USA

^bRFS Pharma, LLC, 1860 Montreal Road, Tucker, GA 30084, USA

Abstract

An efficient method for the synthesis of nucleoside phosphoramidates prodrugs (**6a–f**) has been developed that employs a simple protection/deprotection sequence of the nucleoside with benzyloxycarbonyl (Cbz). The coupling reaction of Cbz-protected derivatives (**5a–f**) with phenyl-(ethoxy-L-alaninyl)-phosphorochloridate (**7**), followed by Cbz group removal by hydrogenolysis provided the phenyl phosphoramidate ProTides (**6a–f**) in excellent overall yields.

Keywords

ProTide; Nucleoside; Monophosphate prodrug; Benzyloxycarbonyl; Antiviral

1. Introduction

Over the past 40 years, nucleoside analogs have established themselves as important agents for first-line antiviral therapy and cancer therapy. In most cases, the observed therapeutic activity does not result directly from the nucleoside itself, but from the corresponding nucleoside 5'-triphosphate (NuTP). However, this three step intracellular conversion by kinases is often limited by an inefficient initial phosphorylation step. Nucleotides cannot be considered as therapeutic agents due to their polar nature, their inability to cross the cell membrane and their dephosphorylation in extracellular fluids. In order to overcome these problems, considerable efforts have focused on monophosphate prodrugs¹ that mask the monophosphate moiety with various chemically or enzymatically cleaved groups once the compound is transported into the cell. This strategy has the potential to reveal potent compounds that were inactive in their nucleoside form because of a lack of phosphorylation. Among all reported prodrugs approach, the class of aryl phosphoramidate nucleoside prodrug (ProTide) developed by McGuigan² has been proven to enhance, in vitro, the activity of parent nucleosides by increasing the formation rate of NuTP by improved intracellular transport and/or bypassing the rate limiting monophosphorylation step.

For instance, 2',3'-dideoxy-3'-deoxythymidine monophosphate prodrug (d4T-MP-PD, **1a**) demonstrated 100-fold more potency against HIV than d4T.³ The phosphoramidate (d4A-MP-PD, **1b**) of 2',3'-dideoxy-2',3'-dideoxyadenosine (d4A) has markedly enhanced anti-HIV activity (ca. 2000-fold) compared to d4A.⁴ Recently, application of the ProTide approach significantly improved antiviral potency of the carbocyclic adenosine

analog L-Cd4A-MP-PD, **1c** (9000-fold) against HIV.⁵ The antiviral potency of both abacavir and carbovir ProTides (**1f** and **1g**) was boosted by 10- and 20-fold, respectively, against hepatitis B virus (HBV).⁶ In the same manner, ProTide derivative (**1h**) of BVDU (brivudin) showed enhanced potency compared to parent compound against colon cancer.⁷ 4'-Azidoadenosine phosphoramidate derivative (**1e**) also exhibited a more potent antiviral activity against HCV replication than the parent compound.⁸ More interestingly, phosphoramidates (**1d**),⁹ (**1i-k**),¹⁰ and (**1l**)¹¹ have been shown to exhibit significant antiviral activity against hepatitis C virus (HCV) replication, while their parent nucleoside was devoid of activity (Fig. 1).

In general, aryl phosphoramidate ProTides are synthesized by direct coupling of an unprotected nucleoside with a phosphorochloridate derivative using either *N*-methyl imidazole (NMI) or *t*-butyl magnesium halide (Br or Cl) in tetrahydrofuran (THF). However, the synthesis of most ProTides is plagued with low to moderate yields due to poor chemoselectivity in the ProTide forming reaction and/or poor solubility of nucleoside in THF. Acid labile protective groups, such as isopropylidene¹² or cyclopentylidene,^{8,13} have been used in the past to prepare phosphoramidate prodrugs of ribonucleosides. However, the phosphorochloridate/nucleoside coupling yields remain moderate and the relative instability of the phosphoramidate function to acidic conditions lead to low yields for the deprotection step. Now that pharmaceutical companies, such as Inhibitex,^{12a} Gilead,¹⁴ Pharmasset,¹⁰ and Idenix¹⁵ are developing their own HCV nucleoside ProTides, there is need for an efficient high yielding synthetic route to prepare these compounds involving simple purifications steps. Herein, we are reporting an efficient method to prepare phenyl phosphoramidate ProTides by protection of polar functional groups (OH and NH₂) with benzyloxycarbonyl chloride (CbzCl) followed by coupling with phosphoramidate **7** and final deprotection under neutral conditions. The benzyloxycarbonyl (Cbz) group was a particularly attractive protective group for its facile introduction on the sugar moiety (and the base moiety in case of a cytidine analog) and also for its clean removal by simple hydrogenation under mild and neutral conditions without affecting the phosphoramidate functional group.

2. Results and discussions

Cytidine (**2a**) was used as a model system and we synthesized the Cbz-protected cytidine analog (**3a**) following previously reported synthetic methods.¹⁶ The selective silylation of the 5'-hydroxyl group of **2a** was conducted with TBSCl and imidazole in pyridine. Additionally, protection of the two remaining hydroxyl groups along with the amino group was preformed with CbzCl to provide a 93% yield after purification of the fully protected cytidine derivative (**3a**) (Scheme 1). The silyl group of **3a** was removed with Et₃N-3HF to afford Cbz-derivative **4a** in quantitative yield. With the lipophilic cytidine derivative (**4a**) in hand, we investigated its coupling with phenyl-(ethoxy-L-alaninyl)-phosphorochloridate (**7**), which was synthesized by the reaction of phenyl-phosphodichloridate with L-alanine ethyl ester hydrochloric salt.⁷ The reaction of Cbz-cytidine **4a** with phosphorochloridate (**7**), using the previously reported procedure,⁷ provided Cbz-cytidine phosphoramidate **5a** in 97% yield. Finally, the hydrogenolysis of Cbz-protected cytidine ProTide (**5a**) in the presence of Pd/C in EtOH provided the cytidine ProTide (**6a**) in 98% yield. With an overall yield of 86% from cytidine (**2a**), it is evident that our new CBz protection/deprotection approach represents a valuable alternative to the direct coupling of cytidine **2a** with phosphorochloridate (**7**) (10% yield).

In order to generalize our strategy, this efficient synthetic route was applied to other natural nucleosides including adenosine (A), guanosine (G), and uridine (U) as summarized in Table 1. The reaction of A and U with TBSCl in pyridine gave 5'-*O*-silylated A and U in high yield. Due to its low solubility in pyridine, the silylation of G was conducted in DMSO.

The reaction of silylated nucleosides (U, A, G) with CbzCl in the presence of DMAP in CH₂Cl₂ afforded their corresponding Cbz-protected compounds in good yields. In accordance with previously reported results,^{16a,16b} formation of *N*⁶-Cbz-protected A and *O*⁶/*N*²-Cbz-protected G derivatives was never observed, even though an excess of CbzCl was used. The treatment of 5'-*O*-silylated Cbz-nucleosides (A, G, and U) with Et₃N-3HF provided Cbz-protected nucleosides (**4b–d**) in excellent yields (Table 1). Finally, the coupling reaction of **4b–d** with phenoxy phosphorochloridate (**7**), followed by hydrogenolysis using either Pd/C, H₂ (A and G) or catalytic hydrogen transfer (U),^{16a} afforded their corresponding phosphoramidate ProTides (**6b–d**) in excellent yield.

The Cbz approach was also applied to the preparation of both 2'-deoxy-2'- α -fluoro-2'- β -*C*-methyl uridine and 2'-deoxy-2'- α -fluoro-2'- β -*C*-methyl-cytidine ProTide **6e** and **6f**; two anti HCV-agents¹⁷ previously prepared by direct coupling of the nucleosides with phosphorochloridate **7** (17% and 20% yields, respectively).¹⁸ The key Cbz protected intermediates (**4e–f**), prepared from their parent nucleosides using the procedure described above (Scheme 1), were reacted with the phenyl-(ethoxy-L-alaninyl)-phosphorochloridate (**7**) to give Cbz-protected ProTides (**5e–f**) in excellent yield. Subsequently, they were converted to their corresponding ProTides (**6e–f**) by hydrogenolysis in quantitative yield (Table 1).

3. Conclusion

In summary, an efficient synthetic procedure for the preparation of aryl phosphoramidate ProTides was successfully developed by utilizing a Cbz protection/deprotection sequence. This method appears to be general and can be applied to *ribo* or 2'-deoxyribo nucleosides bearing various bases (A, G, C, U). The coupling reaction of a variety of Cbz-protected nucleosides (**4a–f**) with phenyl-(ethoxy-L-alaninyl)-phosphorochloridate (**7**) afforded the Cbz-protected ProTides (**5a–f**) in excellent yields (~90%). The removal of the Cbz group from **5a–f** was successfully conducted under hydrogenolysis with Pd/C, hydrogen (1 atm) or catalytic hydrogen transfer to provide the aryl phosphoramidate ProTides (**6a–f**) in near quantitative overall yields. To our knowledge, this approach is one of the most efficient and potentially most general sequences to prepare phosphoramidate nucleoside prodrugs. Its development could significantly impact the multikilo production of clinically relevant compounds, such as **6e** and **6f**.

4. Experimental section

4.1. General

Nuclear magnetic resonance (NMR) spectra (¹H, ¹³C, ¹⁹F, and ³¹P) were recorded on a Varian Unity Plus 400 MHz fourier transform spectrometer at rt, with tetramethylsilane (TMS) as an internal standard. Chemical shifts (δ) are reported in parts per million (ppm), and signals are quoted as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad), dd (doublet of doublets), or ddd (doublet of doublets of doublets). The phosphoramidates are an approximate 50:50 mixture of diastereomers and the ¹³C NMR data is reported as observed, that is, some carbon signals overlap. High-resolution mass spectra (HRMS) were recorded on a Micromass Autospec high-resolution mass spectrometer with electrospray ionization (ESI). Thin-layer chromatography (TLC) was performed on 0.25 mm silica gel. Purifications were carried out on silica gel column chromatography (60 Å, 63–200 μ m, or 40–75 μ m).

4.1.1. 5'-O-tert-Butyldimethylsilyl-N⁴-2',3'-O-tris-benzylox-ycarbonylcytidine (3a)—To a solution of cytidine (3.60 g, 14.3 mmol) in 30 mL of anhydrous pyridine was added imidazole (1.25 g, 18.40 mmol) and *tert*-butyldimethylsilyl chloride (TBDMSCl, 2.40

g, 15.7 mmol) at 0 °C under a N₂ atmosphere. The reaction mixture was stirred at rt for 12 h and then treated with methanol (8.0 mL). After stirring for 60 min, the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (hexane/EtOAc=10:1 to 1:4 v/v) to give (5.12 g, 12.5 mmol) in 97% yield. Subsequently, to a solution of protected cytidine (2.68 g, 7.50 mmol) and DMAP (5.50 g, 45.0 mmol) in 50 mL of anhydrous CH₂Cl₂ was added benzyl chloroformate (CbzCl, 4.76 mL, 33.74 mmol) at 0 °C under N₂ atmosphere. After stirring for 72 h at rt, the reaction mixture was diluted with CH₂Cl₂ (200 mL) and then washed with cold 1.0 M HCl aqueous solution (50 mL) then water (100 mL). The solution was dried over anhydrous MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified on silica gel column chromatography (hexane/EtOAc=10:1 to 1:1 v/v) to give **3a** (5.47 g, 7.20 mmol) in 93% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.32 (d, *J*=8.0 Hz, 1H), 7.58 (br, 1H), 7.42–7.30 (m, 15H), 7.21 (d, *J*=8.0 Hz, 1H), 6.27 (d, *J*=3.2 Hz, 1H), 5.35 (t, *J*=4.0 Hz, 1H), 5.28 (t, *J*=5.6 Hz, 1H), 5.23 (s, 2H), 5.13 (d, *J*=2.4 Hz, 2H), 5.10 (d, *J*=7.6 Hz, 2H), 4.33 (d, *J*=5.6 Hz, 1H), 4.06 (d, *J*=10.8 Hz, 1H), 3.79 (d, *J*=10.8 Hz, 1H), 0.93 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 162.8, 154.7, 153.9, 153.8, 152.5, 144.0, 137.2, 135.1, 134.7, 134.7, 130.7, 129.2, 128.9, 128.8, 128.7, 128.7, 128.6, 128.5, 128.4, 128.3, 117.2, 95.2, 87.8, 81.9, 77.5, 72.7, 70.4, 70.4, 67.9, 61.5, 25.9, 18.4, –5.5, –5.6; MS-ESI⁺ *m/z* 760 (M+H⁺).

4.1.2. N⁴-2',3'-O-Tris-benzoyloxycarbonylcytidine (4a)—To a solution of **3a** (4.50 g, 5.92 mmol) in 20 mL of anhydrous THF was added triethylamine trihydrofluoride (Et₃N–3HF, 6.0 mL, 36.8 mmol) at 0 °C under N₂ atmosphere. The solution was stirred for 12 h at rt and all volatiles were removed using a rotary evaporator. The residue was dissolved in EtOAc (100 mL) and washed with cold saturated NaHCO₃ solution (30 mL×2), and brine (30 mL). The resulting solution was dried over Na₂SO₄ for 3 h and filtered. The filtrate was adsorbed on silica gel and purified by silica gel column chromatography (CH₂Cl₂/MeOH=40:1 to 20:1 v/v) to give **4a** (3.71 g, 5.74 mmol) in 97% yield. ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, *J*=7.6 Hz, 1H), 7.85 (br, 1H), 7.40–7.30 (m, 15H), 7.27 (d, *J*=7.6 Hz, 1H), 5.80–5.75 (m, 2H), 5.51 (t, *J*=4.8 Hz, 1H), 5.21 (s, 2H), 5.14–5.07 (m, 4H), 4.33 (m, 1H), 3.99 (d, *J*=12.0 Hz, 1H), 3.83–3.79 (m, 1H), 3.60 (br, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 174.3, 163.1, 155.2, 154.3, 153.9, 152.3, 146.8, 135.0, 134.8, 128.9, 128.9, 128.8, 128.8, 128.7, 128.6, 95.9, 92.3, 83.8, 75.9, 73.9, 70.6, 70.6, 68.3, 61.5; MS-ESI⁺ *m/z* 646 (M+H⁺).

4.1.3. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphoryl-N⁴-2',3'-O- tris-benzoyloxycarbonylcytidine (5a)—To a solution of **4a** (0.50 g, 0.78 mmol) and **7** (0.46 g, 1.56 mmol) in 10 mL of anhydrous THF was added 1-methylimidazole (0.15 mL, 2.0 mmol) over 10 min at –78 °C under argon atmosphere. After stirring for 2 h at –78 °C, the reaction was maintained for 12 h at rt. The solvent was removed under reduced pressure and the residue was dissolved in CH₂Cl₂ (20 mL), washed with cold 0.5 M HCl solution (5 mL×2), cold water (10 mL), and brine (5 mL). The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (CH₂Cl₂/MeOH=20:1 to 10:1 v/v) to give **5a** (0.68 g, 0.76 mmol), as 1:1 diastereomeric (R_p/S_p) mixture, in 97% yield. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (br, 1H), 7.92–7.34 (m, 1H), 7.38–7.09 (m, 21H), 6.12–6.08 (m, 1H), 5.38–5.30 (m, 1H), 5.21 (br, 2H), 5.15–5.06 (m, 4H), 5.06–5.01 (m, 1H), 4.49–4.30 (m, 1H), 4.20–4.08 (m, 3H), 4.07–3.96 (m, 2H), 3.66–3.51 (m, 1H), 1.43–1.33 (m, 3H), 1.28 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.4, 173.5, 162.9, 154.8, 154.0, 153.9, 152.3, 150.6, 144.4, 135.2, 134.7, 130.1, 130.0, 129.8, 128.8, 128.8, 128.7, 128.6, 128.5, 128.5, 125.3, 125.0, 120.3, 120.2, 95.7, 89.1, 80.1, 76.7, 72.6, 70.9, 68.1, 64.9, 61.8, 50.5, 21.1, 14.2; ³¹P NMR (162 MHz, CDCl₃) δ 3.14, 3.00; MS-ESI⁺ *m/z* 901 (M+H⁺); HRMS-ESI⁺: *m/z* calcd for C₄₄H₄₅N₄O₁₅NaP (M+Na⁺) 923.2530, found 923.2525.

4.1.4. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphorylcytidine (6a)—To a solution of **5a** (0.37 g, 0.41 mmol) in 10 mL of EtOH was added Pd/C (0.02 g, 10% Pd on activated carbon) at rt. The mixture was stirred for 2 h under an atmosphere of H₂ (1 atm) and then treated with Celite (1.0 g) and stirred for 30 min. The suspension was filtered and washed with MeOH (10 mL×3). The collected solution was concentrated under reduced pressure and the residue was purified on silica gel column chromatography (MeOH/EtOAc=1:10 v/v) to give **6a** (0.20 g, 0.40 mmol), as 1:1 diastereomeric (R_P/S_P) mixture, in 98% yield. ¹H NMR (400 MHz, CD₃OD) δ 7.75–7.67 (m, 1H), 7.36–7.31 (m, 2H), 7.24–7.13 (m, 3H), 5.88–5.79 (m, 3H), 4.46–4.26 (m, 2H), 4.18–4.06 (m, 3H), 4.06–4.02 (m, 1H), 3.94–3.85 (m, 1H), 1.33–1.28 (m, 3H), 1.24–1.14 (m, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 175.1, 167.7, 158.6, 142.5, 131.0, 130.2, 126.4, 124.0, 121.6, 121.5, 96.5, 92.1, 83.6, 76.1, 70.8, 67.2, 62.5, 51.8, 20.6, 14.6; ³¹P (162 MHz, CD₃OD) δ 4.89, 4.74; MS-ESI⁺ *m/z* 499 (M+H⁺); HRMS-ESI⁺: *m/z* calcd for C₂₀H₂₇N₄O₉NaP (M+Na⁺) 521.1403, found 521.1408.

4.1.5. 5'-O-tert-Butyldimethylsilyl-2',3'-O-bis-benzyloxycarbonyluridine (3b)—Compound **3b** was prepared using the same procedure as **3a**: yield 96%; ¹H NMR (400 MHz, CDCl₃) δ 9.25 (s, 1H), 7.83 (d, *J*=8.0 Hz, 1H), 7.34–7.31 (m, 10H), 6.28 (d, *J*=4.8 Hz, 1H), 5.72 (d, *J*=8.0 Hz, 1H), 5.30–5.26 (m, 3H), 5.16–5.09 (m, 4H), 4.29 (q, *J*=1.6 Hz, 1H), 3.95 (dd, *J*=2.0, 11.6 Hz, 1H), 3.82 (dd, *J*=2.0, 11.6 Hz, 1H), 0.94 (s, 9H), 0.13 (s, 3H), 0.12 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 163.2, 154.2, 154.0, 150.4, 139.6, 134.7, 134.7, 128.9, 128.8, 128.7, 128.5, 103.2, 85.7, 83.0, 74.3, 70.6, 70.5, 62.8, 60.6, 26.0, 18.5, 14.35, –5.4; MS-ESI⁺ *m/z* 627 (M+H⁺).

4.1.6. 2',3'-O-Bis-benzyloxycarbonyluridine (4b)—Compound **4b** was prepared using the same procedure as **4a**: yield 99%; ¹H NMR (400 MHz, CDCl₃) δ 9.69 (s, 1H), 7.64 (d, *J*=8.0 Hz, 1H), 7.35–7.30 (m, 10H), 5.96 (d, *J*=6.0 Hz, 1H), 5.74 (d, *J*=8.0 Hz, 1H), 5.54 (dd, *J*=5.2, 6.0 Hz, 1H), 5.45 (dd, *J*=3.6, 5.2 Hz, 1H), 5.12–5.05 (m, 4H), 4.25 (d, *J*=2.4 Hz, 1H), 3.89 (d, *J*=12.0 Hz, 1H), 3.80 (m, 1H), 3.69 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 163.8, 154.3, 154.0, 150.6, 141.7, 134.7, 134.6, 128.8, 128.8, 128.7, 128.5, 103.3, 88.6, 83.3, 75.8, 74.4, 70.7, 70.5, 61.7, 39.2; MS-ESI⁺ *m/z* 513 (M+H⁺).

4.1.7. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphoryl-2',3'-O-bis-benzyl-oxycarbonyluridine (5b)—Compound **5b** was prepared using the same procedure as **5a**: yield 98% (1:1 diastereomeric (R_P/S_P) mixture). ¹H NMR (400 MHz, CDCl₃) δ 10.11–10.00 (m, 1H), 7.89 (d, *J*=8.0 Hz, 0.5H), 7.46 (d, *J*=8.8 Hz, 0.5H), 7.31–7.22 (m, 15H), 6.13–6.10 (m, 1H), 5.75–5.69 (m, 0.5H), 5.56–5.48 (m, 0.5H), 5.46–5.41 (m, 1H), 5.30 (t, *J*=5.6 Hz, 0.5H), 5.20 (t, *J*=5.6 Hz, 0.5H), 5.14–5.04 (m, 4H), 4.48–4.32 (m, 2H), 4.23–4.08 (m, 3H), 4.08–3.96 (m, 1H), 3.85–3.76 (m, 1H), 1.34–1.33 (m, 3H), 1.26–1.18 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 173.6, 173.4, 163.4, 153.9, 150.4, 139.8, 134.5, 129.9, 129.8, 129.6, 129.6, 128.7, 128.6, 128.6, 128.4, 128.4, 128.3, 103.4, 86.9, 86.3, 83.3, 80.2, 76.0, 75.5, 74.6, 73.1, 70.4, 70.2, 65.3, 61.6, 61.4, 60.4, 53.6, 50.2, 20.8, 14.0; ³¹P (162 MHz, CDCl₃) δ 4.13, 4.07; MS-ESI⁺ *m/z* 768 (M+H⁺); HRMS-ESI⁺: *m/z* calcd for C₃₆H₃₈N₃O₁₄NaP (M+Na⁺) 790.2001, found 790.1997.

4.1.8. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphoryluridine (6b)—To a solution of **5b** (0.50 g, 0.65 mmol) in 10 mL of EtOH was added 1,4-cyclohexadiene (1.30 mL) and Pd/C (0.03 g, 10% Pd on activated carbon) at rt. After stirring for 3 h at rt, the reaction mixture was treated with Celite (2.0 g) and stirred for 30 min. The suspension was filtered and washed with MeOH (15 mL×3). The collected solution was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (MeOH/EtOAc=1:10 v/v) to give **6b** (0.32 g, 0.64 mmol), as a 1:1 diastereomeric (R_P/S_P) mixture, in 98% yield. ¹H NMR (400 MHz, CD₃OD) δ 7.70 (d, *J*=8.0 Hz, 0.5H), 7.63 (d, *J*=8.0 Hz,

0.5H), 7.39–7.33 (m, 2H), 7.27–7.18 (m, 3H), 5.91 (d, $J=8.8$ Hz, 0.5H), 5.89 (d, $J=8.8$ Hz, 0.5H), 5.69 (d, $J=8.0$ Hz, 0.5H), 5.61 (d, $J=8.0$ Hz, 0.5H), 4.44–4.29 (m, 2H), 4.19–4.09 (m, 5H), 3.98–3.91 (m, 1H), 3.87–3.76 (m, 1H), 1.36–1.30 (m, 3H), 1.25–1.21 (m, 3H); ^{13}C NMR (100 MHz, CD_3OD) δ 175.2, 166.2, 152.2, 142.4, 131.0, 130.8, 126.4, 126.2, 121.5, 103.2, 90.8, 84.0, 75.3, 71.1, 67.4, 62.5, 62.4, 51.7, 20.6, 14.6; ^1P (162 MHz, CD_3OD) δ 4.94, 4.76; MS-ESI $^+$ m/z 500 ($\text{M}+\text{H}^+$); HRMS-ESI $^+$: m/z calcd for $\text{C}_{20}\text{H}_{26}\text{N}_3\text{O}_{10}\text{NaP}$ ($\text{M}+\text{Na}^+$) 522.1253, found 522.1256.

4.1.9. 5'-O-tert-Butyldimethylsilyl-2',3'-O-bis-benzylox-ycarbonyl-adenosine

(3c)—Compound **3c** was prepared using the same procedure as **3a**: yield 92% (two steps); ^1H NMR (400 MHz, CDCl_3) δ 8.33 (s, 1H), 8.15 (s, 1H), 7.37–7.29 (m, 10H), 6.33 (d, $J=6.4$ Hz, 1H), 5.81 (dd, $J=4.8$, 6.0 Hz, 1H), 5.66 (br, 2H), 5.52 (dd, $J=4.8$, 6.0 Hz, 1H), 5.17–5.05 (m, 4H), 4.37 (q, $J=2.8$ Hz, 1H), 3.95 (dd, $J=2.8$, 11.6 Hz, 1H), 3.80 (dd, $J=2.8$, 11.6 Hz, 1H), 0.94 (s, 9H), 0.13 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 155.6, 154.4, 153.9, 153.6, 150.3, 142.8, 138.9, 134.8, 134.7, 128.9, 128.9, 128.9, 128.8, 128.6, 120.0, 85.0, 83.3, 77.0, 74.7, 70.6, 70.5, 62.9, 26.1, –5.2, –5.3; MS-ESI $^+$ m/z 650 ($\text{M}+\text{H}^+$).

4.1.10. 2',3'-Bis-benzyloxycarbonyl-adenosine (4c)

—Compound **4c** was prepared using the same procedure as **4a**: yield 98%; ^1H NMR (400 MHz, CDCl_3) δ 8.25 (s, 1H), 7.71 (s, 1H), 7.36–7.27 (m, 10H), 7.00 (d, $J=10.8$ Hz, 2H), 6.85 (br, 2H), 6.10 (dd, $J=4.8$, 7.6 Hz, 1H), 6.03 (d, $J=7.6$ Hz, 1H), 5.70 (d, $J=4.8$ Hz, 1H), 5.16–5.01 (m, 4H), 4.43 (s, 1H), 3.97 (d, $J=12.4$ Hz, 1H), 3.83 (t, $J=12.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.4, 154.2, 153.6, 152.7, 148.3, 140.2, 134.7, 134.5, 128.8, 128.7, 128.7, 128.6, 128.5, 87.7, 85.8, 76.1, 75.6, 70.6, 70.3, 62.6, 60.4, 21.1, 14.2; MS-ESI $^+$ m/z 536 ($\text{M}+\text{H}^+$).

4.1.11. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphoryl-2',3'-O-bis-benzyl-oxycarbonyl-adenosine (5c)

—Compound **5c** was prepared using the same procedure as **5a**: yield 92% (1:1 diastereomeric (R_p/S_p) mixture); ^1H NMR (400 MHz, CDCl_3) δ 8.29 (s, 0.5H), 8.26 (s, 0.5H), 7.99 (s, 0.5H), 7.93 (s, 0.5H), 7.34–7.19 (m, 15H), 6.25 (br, 2H), 6.19–6.17 (m, 1H), 6.02–5.93 (m, 1H), 5.72 (m, 1H), 5.13–5.03 (m, 7H), 4.54–4.37 (m, 2H), 4.14–3.96 (m, 2H), 1.35–1.25 (m, 3H), 1.18 (m, 3H); δ –158.03; ^{13}C NMR (100 MHz, CDCl_3) δ 173.7, 173.6, 155.8, 154.1, 153.8, 153.3, 150.7, 149.8, 139.6, 134.6, 129.9, 128.9, 128.8, 128.7, 128.6, 125.1, 120.4, 120.3, 120.2, 85.9, 80.7, 75.8, 73.6, 70.6, 65.3, 50.4, 47.9, 21.0, 14.2; ^{31}P (162 MHz, CDCl_3) δ 3.23, 3.16; MS-ESI $^+$ m/z 791 ($\text{M}+\text{H}^+$); HRMS-ESI $^+$: m/z calcd for $\text{C}_{37}\text{H}_{40}\text{N}_6\text{O}_{12}\text{P}$ ($\text{M}+\text{H}^+$) 791.2435, found 791.2436.

4.1.12. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphoryl-adenosine (6c)

—Compound **6c** was prepared using the same procedure as **6a**: yield 94% (1:1 diastereomeric (R_p/S_p) mixture); ^1H NMR (400 MHz, CD_3OD) δ 8.25–8.16 (m, 2H), 7.31–7.28 (m, 2H), 7.20–7.11 (m, 3H), 6.02 (t, $J=4.8$ Hz, 1H), 4.66–4.61 (m, 1H), 4.45–4.30 (m, 3H), 4.29–4.23 (m, 1H), 4.09–4.01 (m, 2H), 3.91–3.08 (m, 1H), 1.27–1.20 (m, 3H), 1.18–1.13 (m, 3H); ^{13}C NMR (100 MHz, CD_3OD) δ 175.1, 157.4, 154.1, 152.2, 150.8, 141.1, 130.9, 130.1, 126.3, 121.5, 121.5, 120.6, 90.0, 84.5, 75.5, 71.7, 67.4, 62.5, 51.7, 20.5, 14.6; ^{31}P (162 MHz, CD_3OD) δ 4.93, 4.78; MS-ESI $^+$ m/z 523 ($\text{M}+\text{H}^+$); HRMS-ESI $^+$: m/z calcd for $\text{C}_{21}\text{H}_{27}\text{N}_6\text{O}_8\text{NaP}$ ($\text{M}+\text{Na}^+$) 545.1517, found 545.1515.

4.1.13. 5'-O-tert-Butyldimethylsilyl-2',3'-O-bis-benzyloxycarbonyl-guanosine (3d)

—To a solution of guanosine (2.0 g, 7.06 mmol) in 20 mL of anhydrous DMSO was added DMAP (0.09 g, 0.71 mmol), Et_3N (1.07 g, 10.6 mmol), and TBSCl (1.17 g, 7.76 mmol) at 0 °C under N_2 atmosphere. After stirring for 24 h at rt, 20 mL of anhydrous CH_2Cl_2 , CbzCl (4.82 g, 28.24 mmol), and DMAP (4.32 g, 35.30 mmol) was added to the solution at 0 °C under N_2 atmosphere. After stirring for 48 h at rt, the reaction mixture was

concentrated under reduced pressure and the residue was dissolved in CH₂Cl₂ (100 mL) and washed with cold 0.5 M HCl solution (30 mL×2), cold water (30 mL), and brine (30 mL). The organic layer was dried over Na₂SO₄, and filtered. The filtrate was concentrated and purified by silica gel column chromatography (CH₂Cl₂/MeOH=30:1 to 10:1 v/v) to give **3d** (4.32 g, 6.49 mmol) in 92% yield. ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.74 (br, 1H), 7.85 (s, 1H), 7.40–7.29 (m, 10H), 6.57 (br, 2H), 5.99 (d, *J*=7.2 Hz, 1H), 5.67 (dd, *J*=5.2, 7.2 Hz, 1H), 5.40 (dd, *J*=2.8, 5.2 Hz, 1H), 5.18–5.10 (m, 4H), 4.30 (q, *J*=3.6 Hz, 1H), 3.87 (d, *J*=3.6 Hz, 2H), 0.89 (s, 9H), 0.09 (3H), 0.08 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 173.7, 156.6, 154.1, 153.5, 153.1, 151.3, 135.0, 134.8, 134.3, 128.7, 128.6, 128.5, 128.4, 128.2, 116.4, 82.9, 82.4, 76.1, 74.6, 69.9, 69.7, 62.8, 47.3, 33.9, 25.8, 25.5, 18.0, –5.5, –5.6; MS-ESI⁺ *m/z* 666 (M+H⁺); HRMS-ESI⁺: *m/z* calcd for C₃₂H₄₀N₅O₉Si (M+H⁺) 666.2601, found 666.2603.

4.1.14. 2',3'-O-Bis-benzyloxycarbonylguanosine (4d)—Compound **4d** was prepared using the same procedure as **4a**: yield 92%; ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.72 (br, 1H), 7.99 (s, 1H), 7.38–7.29 (m, 10H), 6.55 (br, 2H), 5.98 (d, *J*=7.6 Hz, 1H), 5.72 (dd, *J*=5.2, 7.6 Hz, 1H), 5.47 (t, *J*=5.2 Hz, 1H), 5.42 (dd, *J*=2.0, 5.2 Hz, 1H), 5.17–5.06 (m, 5H), 4.26 (q, *J*=2.0 Hz, 1H), 3.68 (m, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 186.5, 175.4, 173.7, 156.6, 154.0, 153.6, 153.1, 151.2, 135.2, 135.0, 134.9, 128.6, 128.6, 128.5, 128.5, 128.4, 128.2, 116.5, 83.1, 83.1, 76.1, 75.1, 69.8, 69.6, 60.9, 47.3; MS-ESI⁺ *m/z* 552 (M+H⁺); HRMS-ESI⁺: *m/z* calcd for C₂₆H₂₆N₅O₉ (M+H⁺) 552.2601, found 552.2603.

4.1.15. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphoryl-2',3'-O-bis-benzyl-oxycarbonylguanosine (5d)—Compound **5d** was prepared using the same procedure as **5a**: yield 90% (1:1 diastereomeric (R_P/S_P) mixture); ¹H NMR (400 MHz, CD₃OD) δ 7.73 (s, 1H), 7.31–7.13 (m, 15H), 7.10 (s, 1H), 7.00 (s, 1H), 6.07 (t, *J*=6.0 Hz, 1H), 5.89 (t, *J*=6.0 Hz, 0.5H), 5.81 (t, *J*=6.0 Hz, 0.5H), 5.69–5.64 (m, 1H), 5.16–5.01 (m, 5H), 4.45–4.32 (m, 3H), 4.09–4.04 (m, 2H), 3.94–3.85 (m, 1H), 1.29–1.23 (m, 3H), 1.16 (t, *J*=5.8 Hz, 3H); ¹³C NMR (100 MHz, CD₃OD) δ 175.2, 175.0, 159.4, 155.6, 155.3, 153.0, 152.2, 138.9, 138.4, 136.6, 131.0, 130.9, 130.0, 129.8, 129.8, 129.6, 129.6, 129.5, 128.1, 126.4, 122.3, 121.6, 87.2, 82.0, 77.2, 75.2, 71.6, 66.8, 62.5, 51.7, 34.1, 20.5, 14.6; ³¹P (162 MHz, CD₃OD) δ 4.98, 4.84; MS-ESI⁺ *m/z* 807 (M+H⁺); HRMS-ESI⁺: *m/z* calcd for C₃₇H₄₀N₆O₁₃P (M+H⁺) 807.2399, found 807.2399.

4.1.16. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphorylguanosine (6d)—Compound **6d** was prepared using the same procedure as **6a**: yield 95% (1:1 diastereomeric (R_P/S_P) mixture); ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.73 (br, 1H), 7.84 (s, 1H), 7.38–7.14 (m, 5H), 6.57 (br, 2H), 6.11–6.02 (m, 1H), 5.76–5.71 (m, 1H), 5.56 (m, 1H), 5.37–5.33 (m, 1H), 4.43–4.39 (m, 1H), 4.24–3.98 (m, 6H), 3.80 (m, 1H), 1.23–1.18 (m, 3H), 1.15–1.10 (m, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 173.3, 173.2, 156.8, 153.8, 151.5, 150.7, 135.3, 130.0, 129.6, 124.6, 120.2, 116.7, 86.3, 82.5, 73.2, 70.2, 66.0, 60.6, 49.8, 19.7, 14.0; ³¹P (162 MHz, DMSO-*d*₆) δ 4.66, 4.65; MS-ESI⁺ *m/z* 539 (M+H⁺); HRMS-ESI⁺: *m/z* calcd for C₂₁H₂₇N₆O₉NaP (M+Na⁺) 561.1468, found 561.1469.

4.1.17. 5'-O-tert-Butyldimethylsilyl-3'-O-benzyloxycarbonyl-2'-fluoro-2'-methyluridine (3e)—Compound **3e** was prepared using the same procedure as **3a**: yield 98% (two steps); ¹H NMR (400 MHz, CDCl₃) δ 9.90 (br, 1H), 8.05 (d, *J*=8.0 Hz, 1H), 7.40–7.35 (m, 5H), 6.27 (d, *J*=17.6 Hz, 1H), 5.72 (dd, *J*=1.6, 8.0 Hz, 1H), 5.20 (dd, *J*=12.0, 25.6 Hz, 2H), 5.16 (dd, *J*=9.6, 22.0 Hz, 1H), 4.26 (dd, *J*=1.2, 9.6 Hz, 1H), 4.10 (dd, *J*=1.2, 12.0 Hz, 1H), 3.71 (dd, *J*=1.2, 12.0 Hz, 1H), 1.42 (d, *J*=22.4 Hz, 3H), 0.91 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 163.5, 154.4, 150.7, 139.5, 134.6, 129.0, 128.8, 128.7, 103.1, 100.7, 98.9, 89.0 (d, *J*=39.3 Hz), 79.6, 77.4, 73.7 (d, *J*=15.4 Hz), 70.9,

60.0, 25.9, 18.5, 17.1 (d, $J=24.7$ Hz), -5.5 , -5.7 ; ^{19}F (376 MHz, CDCl_3) δ -159.70 , 159.74 ; MS-ESI $^+$ m/z 509 ($\text{M}+\text{H}^+$); HRMS-ESI $^+$: m/z calcd for $\text{C}_{24}\text{H}_{34}\text{FN}_2\text{O}_7\text{Si}$ ($\text{M}+\text{H}^+$) 509.2126, found 509.2127.

4.1.18. 3'-Benzyloxycarbonyl-2'-fluoro-2'-methyluridine (4e)—Compound **4e** was prepared using the same procedure as **4a**: yield 98%; ^1H NMR (400 MHz, CD_3OD) δ 8.06 (d, $J=8.0$ Hz, 1H), 7.40–7.31 (m, 5H), 6.13 (d, $J=18.4$ Hz, 1H), 5.73 (d, $J=8.0$ Hz, 1H), 5.20 (s, 2H), 5.18 (dd, $J=8.8$, 20.8 Hz, 1H), 4.17 (dd, $J=1.2$, 8.8 Hz, 1H), 3.95 (dd, $J=2.0$, 13.2 Hz, 1H), 3.71 (dd, $J=2.8$, 13.2 Hz, 1H), 1.36 (d, $J=22.8$ Hz, 3H); ^{13}C NMR (100 MHz, CD_3OD) δ 165.8, 156.0, 152.3, 142.0, 136.7, 129.8, 129.8, 129.5, 103.4, 102.0, 100.2, 91.1 (d, $J=38.2$ Hz), 81.4, 75.9 (d, $J=15.5$ Hz), 71.6, 60.1, 17.8 (d, $J=25.5$ Hz); ^{19}F (376 MHz, CD_3OD) δ -159.56 ; MS-ESI $^+$ m/z 395 ($\text{M}+\text{H}^+$); HRMS-ESI $^+$: m/z calcd for $\text{C}_{18}\text{H}_{19}\text{FN}_2\text{O}_7\text{Na}$ ($\text{M}+\text{Na}^+$) 417.1069, found 417.1069.

4.1.19. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphoryl-3'-O-benzyloxy-carbonyl-2'-fluoro-2'-methyluridine (5e)—Compound **5e** was prepared using the same procedure as **5a**: yield 96% (1:1 diastereomeric ($\text{R}_\text{P}/\text{S}_\text{P}$) mixture); ^1H NMR (400 MHz, CDCl_3) δ 9.42–9.28 (m, 1H), 7.49–7.42 (m, 1H), 7.39–7.28 (m, 6H), 7.24–7.13 (m, 4H), 6.20 (br, 1H), 5.71–5.50 (m, 1H), 5.23–5.14 (m, 2H), 5.12–5.03 (m, 1H), 4.61–4.55 (m, 1H), 4.38–4.33 (m, 2H), 4.27–4.21 (m, 1H), 4.19–4.11 (m, 2H), 4.08–3.96 (m, 1H), 1.43–1.30 (m, 6H), 1.28–1.20 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.2, 162.9, 154.4, 150.3, 139.3, 134.7, 130.1, 129.8, 129.1, 129.1, 128.9, 128.9, 128.7, 128.6, 125.4, 125.0, 120.3, 120.2, 103.4, 100.1, 98.3, 77.7, 74.7, 71.1, 61.9, 50.5, 21.2, 17.6, 14.3; ^{19}F (376 MHz, CDCl_3) δ -159.56 ; ^{31}P (162 MHz, CDCl_3) δ 5.87, 5.90; MS-ESI $^+$ m/z 650 ($\text{M}+\text{H}^+$); HRMS-ESI $^+$: m/z calcd for $\text{C}_{29}\text{H}_{34}\text{FN}_3\text{O}_{11}\text{P}$ ($\text{M}+\text{H}^+$) 650.1918, found 650.1923.

4.1.20. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphoryl-2'-fluoro-2'-methyluridine (6e)—Compound **6e** was prepared using the same procedure as **6b**: yield 96% (1:1 diastereomeric ($\text{R}_\text{P}/\text{S}_\text{P}$) mixture); ^1H NMR (400 MHz, CDCl_3) δ 10.05 (br, 1H), 7.50–7.14 (m, 6H), 6.17 (d, $J=18.4$ Hz, 1H), 5.70–5.54 (m, 1H), 4.59–4.31 (m, 3H), 4.30–4.22 (m, 1H), 4.20–4.11 (m, 2H), 4.07–3.96 (m, 1H), 3.94–3.78 (m, 1H), 3.46 (m, 1H), 1.41–1.28 (m, 6H), 1.27–1.22 (m, 3H); ^{19}F (376 MHz, CDCl_3) δ -162.41 ; ^{31}P (162 MHz, CDCl_3) δ 4.01, 3.58; MS-ESI $^+$ m/z 516 ($\text{M}+\text{H}^+$).

4.1.21. 5'-O-tert-Butyldimethylsilyl-N⁴-3'-O-bis-benzyloxycarbonyl-2'-fluoro-2'-methylcytidine (3f)—Compound **3f** was prepared using the same procedure as **3a**: yield 93% (two steps); ^1H NMR (400 MHz, CDCl_3) δ 8.44 (d, $J=7.2$ Hz, 1H), 7.40–7.26 (m, 11H), 7.20 (br, 1H), 6.39 (d, $J=17.2$ Hz, 1H), 5.24–5.12 (m, 5H), 4.28 (dd, $J=1.2$, 9.2 Hz, 1H), 4.12 (dd, $J=1.6$, 12.0 Hz, 1H), 3.72 (dd, $J=1.6$, 12.0 Hz, 1H), 1.37 (d, $J=24.4$ Hz, 3H), 0.93 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.3, 162.7, 154.4, 144.1, 137.3, 135.1, 134.6, 130.5, 129.4, 129.0, 128.9, 128.8, 128.7, 128.6, 128.4, 127.6, 127.1, 117.3, 101.0, 99.1, 89.8 (d, $J=3.9$ Hz), 79.5, 73.6 (d, $J=1.6$ Hz), 70.8, 68.1, 65.3, 60.0, 26.0, 18.6, 17.0 (d, $J=1.6$ Hz), -5.5 , -5.6 ; MS-ESI $^+$ m/z 642 ($\text{M}+\text{H}^+$); HRMS-ESI $^+$: m/z calcd for $\text{C}_{32}\text{H}_{41}\text{FN}_3\text{O}_8\text{Si}$ ($\text{M}+\text{H}^+$) 642.2665, found 642.2642.

4.1.22. N⁴-3'-O-Bis-benzyloxycarbonyl-2'-fluoro-2'-methylcytidine (4f)—Compound **4f** was prepared using the same procedure as **4a**: yield 99%; ^1H NMR (400 MHz, CDCl_3) δ 8.45 (br, 1H), 8.16 (s, 1H), 7.45–7.32 (m, 10H), 7.05 (s, 1H), 6.33 (d, $J=7.6$ Hz, 1H), 5.41 (s, 1H), 5.20–5.15 (m, 4H), 4.26 (d, $J=9.2$ Hz, 1H), 4.12 (d, $J=12.8$ Hz, 1H), 3.79 (d, $J=12.0$ Hz, 1H), 1.38 (d, $J=22.4$ Hz, 1H), 1.381 (d, $J=22.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 162.9, 154.9, 148.7, 144.8, 137.3, 135.1, 134.4, 130.6, 129.3, 129.0, 128.9, 128.8, 128.8, 128.6, 128.5, 117.3, 101.0, 95.9, 80.0, 74.2 (d, $J=1.6$ Hz), 70.8, 70.1, 68.1,

65.3, 59.2, 17.0 (d, $J=2.6$ Hz); ^{19}F (376 MHz, CDCl_3) δ -159.89; MS-ESI $^+$ m/z 528 ($\text{M}+\text{H}^+$); HRMS-ESI $^+$: m/z calcd for $\text{C}_{26}\text{H}_{27}\text{FN}_3\text{O}_8$ ($\text{M}+\text{H}^+$) 528.1776, found 528.1777.

4.1.23. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphoryl-N⁴-3'-O-bis-benzoyloxycarbonyl-2'-fluoro-2'-methylcytidine (5f)—Compound **5f** was prepared using the same procedure as **5a**: yield 93% (1:1 diastereomeric (R_P/S_P) mixture); ^1H NMR (400 MHz, CDCl_3) δ 8.14 (s, 1H), 7.86 (m, 1H), 7.46–7.06 (m, 16H), 6.35 (br, 1H), 5.24–5.15 (m, 4H), 5.14–5.05 (m, 1H), 4.62–4.55 (m, 1H), 4.42–4.33 (m, 2H), 4.29–4.22 (m, 1H), 4.20–4.12 (m, 2H), 4.09–3.93 (m, 1H), 1.41–1.35 (m, 3H), 1.34–1.31 (m, 3H), 1.26–1.20 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.7, 162.8, 154.9, 154.3, 152.3, 150.7, 143.8, 137.3, 135.1, 134.4, 130.8, 130.1, 130.0, 129.4, 129.1, 128.9, 128.6, 128.6, 128.5, 125.4, 120.2, 120.1, 117.3, 100.4, 95.8, 77.5, 74.7, 71.0, 70.0, 68.2, 65.5, 64.9, 61.8, 50.5, 21.1, 17.4, 14.3; ^{19}F (376 MHz, CDCl_3) δ -158.94; MS-ESI $^+$ m/z 783 ($\text{M}+\text{H}^+$); HRMS-ESI $^+$: m/z calcd for $\text{C}_{37}\text{H}_{41}\text{FN}_4\text{O}_{12}\text{P}$ ($\text{M}+\text{H}^+$) 783.2447, found 783.2451.

4.1.24. 5'-O-[Phenyl(ethoxy-L-alaninyl)]phosphoryl-2'-fluoro-2'-methylcytidine (6f)—Compound **6f** was prepared using the same procedure as **6a**: yield 95% (1:1 diastereomeric (R_P/S_P) mixture); ^1H NMR (400 MHz, CD_3OD) δ 7.66–7.50 (m, 1.0 H), 7.40–7.29 (m, 2H), 7.26–7.16 (m, 3H), 6.22 (br, 1H), 5.86–5.78 (m, 1H), 4.60–4.47 (m, 1H), 4.45–4.35 (m, 1H), 4.33–4.22 (m, 1H), 4.17–4.06 (m, 3H), 3.97–3.77 (m, 2H), 1.38–1.18 (m, 9H); ^{19}F (376 MHz, CD_3OD) δ -162.81; ^{31}P (162 MHz, CD_3OD) δ 4.94, 4.80; MS-ESI $^+$ m/z 515 ($\text{M}+\text{H}^+$).

Acknowledgments

This work was supported in part by NIH grant 1R01-AI071846, 5R37-AI-025899, 5R37-AI-041980, 5P30-AI-50409 (CFAR), and by the Department of Veterans Affairs. Dr. Schinazi is the founder and a major shareholder of RFS Pharma, LLC. Emory received no funding from RFS Pharma, LLC to perform this work and vice versa.

References and notes

- For reviews on phosphates and phosphonates prodrugs: Bobeck DR, Coats SJ, Schinazi RF. *Antiviral Ther.* 2010; 15:935–950. Erion MD, Hecker SJ. *J Med Chem.* 2008; 51:2328–2345. [PubMed: 18237108] Schultz C. *Bioorg Med Chem.* 2003; 11:885–898. [PubMed: 12614874]
- For a recent review on the ProTide approach see: Mehellou Y, Balzarini J, McGuigan C. *ChemMedChem.* 2009; 4:1779–1791. [PubMed: 19760699]
- Siddiqui AQ, Ballatore C, McGuigan C, De Clercq E, Balzarini J. *J Med Chem.* 1999; 42:393–399. [PubMed: 9986709]
- McGuigan C, Wedgwood OM, De Clercq E, Balzarini J. *Bioorg Med Chem Lett.* 1996; 6:2359–2362.
- McGuigan C, Hassan-Abdallah A, Srinivasan S, Wang Y, Siddiqui A, Daluge SM, Gudmundsson KS, Zhou H, McLean EW, Peckham JP, Burnette TC, Marr H, Hazen R, Condready LD, Johnson L, Balzarini J. *J Med Chem.* 2006; 49:7215–7226. [PubMed: 17125274]
- McGuigan C, Harris SA, Daluge SM, Gudmundsson KS, McLean EW, Burnette TC, Marr H, Hazen R, Condready LD, Johnson L, De Clercq E, Balzarini J. *J Med Chem.* 2005; 48:3504–3515. [PubMed: 15887959]
- (a) McGuigan C, Thiery JC, Daverio F, Jiang WG, Davies G, Mason M. *Bioorg Med Chem.* 2005; 13:3219–3227. [PubMed: 15809157] (b) Congiatu C, Brancale A, Mason MD, Jiang WG, McGuigan C. *J Med Chem.* 2006; 49:452–455. [PubMed: 16420029]
- Perrone P, Daverio F, Valente R, Rajyaguru S, Martin JA, Leveque V, Pogam SL, Najera I, Klumpp K, Smith DB, McGuigan C. *J Med Chem.* 2007; 50:5463–5470. [PubMed: 17914786]
- Perrone P, Luoni GM, Kelleher MR, Daverio F, Angell A, Mulready S, Congiatu C, Rajyaguru S, Martin JA, Leveque V, Pogam SL, Najera I, Klumpp K, Smith DB, McGuigan C. *J Med Chem.* 2007; 50:1840–1849. [PubMed: 17367121]

10. Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakondfa S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HMM, Niu C, Otto MJ, Furman PA. *J Med Chem.* 2010; 53:7202–7218. [PubMed: 20845908]
11. Rondla R, Coats SJ, McBrayer TR, Grier J, Johns M, Tharnish PM, Whitaker T, Zhou L, Schinazi RF. *Antiviral Chem Chemother.* 2009; 20:99–106.
12. (a) McGuigan C, Gilles A, Madela K, Aljarah M, Holl S, Jones S, Vernachio J, Hutchins J, Ames B, Bryant KD, Gorovits E, Ganguly B, Hunley D, Hall A, Kolykhalov A, Liu Y, Muhammad J, Raja N, Walters R, Wang J, Chamberlain S, Henson G. *J Med Chem.* 2010; 53:4949–4957. [PubMed: 20527890] (b) McGuigan C, Perrone P, Madela K, Neyts J. *Bioorg Med Chem Lett.* 2009; 19:4316–4320. [PubMed: 19523820]
13. Derudas M, Brancale A, Naesens L, Neyts J, Balzarini J, McGuigan C. *Bioorg Med Chem.* 2010; 18:2748–2755. [PubMed: 20207546]
14. Birkus G, Kutty N, He GX, Mulato A, Lee W, McDermott M, Cihlar T. *Antiviral Res.* 2007; 74:A57.
15. Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-Bolyai J, Mayers D. *Antimicrob Agents Chemother.* 2011; 55:76–81. [PubMed: 21060109]
16. (a) Johnson DC II, Widlanski TS. *Org Lett.* 2004; 6:4643–4646. [PubMed: 15575650] (b) Watkins BE, Kiely JS, Rapoport H. *J Am Chem Soc.* 1982; 104:5702–5708. (c) Wandzik I, Bieg T, Kadela M. *Nucleosides, Nucleotides Nucleic Acids.* 2008; 27:1250–1256. [PubMed: 19003570]
17. Sofia, MJ.; Du, J.; Wang, P.; Nagarathnam, D. WO2008121634. 2008.
18. Our attempts to apply this method to ProTides with a 2'- β -C-methyl sugar have been unsuccessful due to formation of a 2',3'-carbonate during the CbzCl reaction.

Fig. 1.
Antiviral phosphoramidate ProTides (**1a-l**).

Scheme 1.
Synthesis of the cytidine ProTide **6a**.

Table 1

Synthesis of nucleoside aryloxy phosphoramidate prodrugs **6a–6f**

Entry	Yields				
	Protection (three steps)	Coupling reaction	Hydrogenolysis (Method A/B) ^a	Overall yield (%)	
1	92%	96%	97% (A)	86(10) ^b	
2	96%	98%	98% (B)	92	
3	90%	92%	94% (A)	79	
4	85%	90%	95% (A)	73	
5	96%	96%	96% (B)	87(19.6) ^c	
6	95%	93%	95% (A)	86(17) ^b	

^a Method A: Pd/C, H₂ (1 atm), EtOH; Method B: Pd/C, 1,4-cyclohexadiene, EtOH.

^bYield for the coupling of unprotected nucleoside with **7**.

^cYield for the coupling of unprotected nucleoside with **7**, see Ref. 18.